LNP023
CLNP023A2002B
Phase 3 small_molecule active
Quick answer
LNP023 for Primary IgA Nephropathy is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Primary IgA Nephropathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active